Philip Felgner

Philip Felgner, PhD is a Professor in Residence in the Department of Physiology and Biophysics at the University of California, Irvine School of Medicine. His research focuses on immunological diagnostic technologies with particular expertise in antigen microarray development.

Dr. Felgner's research interests center on immunological diagnostic methods, particularly in the field of coronavirus research and antibody detection. His work bridges basic science with practical diagnostic applications, with significant contributions to understanding immune responses to viral pathogens. His laboratory has developed innovative antigen microarray technologies that enable comprehensive profiling of antibody responses.

His most recent prominent work involves the development and validation of a coronavirus antigen microarray for detecting SARS-CoV-2 antibodies, which has applications in diagnosis, epidemiological studies, and research into clinical outcomes. This technology demonstrates high sensitivity and specificity in distinguishing between convalescent and naive serum samples.

Dr. Felgner serves as the largest shareholder of Nanommune Inc., a private company that has commercialized the coronavirus antigen microarray technology developed through his research. This demonstrates his commitment to translating basic research findings into practical diagnostic tools.